Date: 2014-05-05
Type of information:
phase: preclinical
Announcement: preclinical results
Company: reMYND (Belgium)
Product: ReS39
Action
mechanism: ReS39 employs a novel mechanism which the researchers think enables body cells to be more resilient to the detrimental effects posed by altered diet and ensuing soaring blood glucose levels.
Disease: type 2 diabetes mellitus
Therapeutic area: Metabolic diseases
Country:
Trial details:
Latest
news: * On May 5th, 2014, reMYND has announced that its experimental diabetes drug ReS39 has demonstrated a strong disease modifying effect in mice, in which the insulin producing capacity of β-cells is preserved – possibly even restored– in a durable way through a novel mechanism of action. Type 2 Diabetes Mellitus (T2DM) is characterised by abnormally high levels of blood glucose caused by non-responsiveness of tissues such as muscle and liver to insulin, i.e. insulin resistance, combined with a failure of the β-cells to produce sufficient insulin. reMYND focuses on the development of small molecules to protect β-cells from extracellular stressors known to negatively impact β-cell function and survival in humans.
Treatment of diabetic mice with experimental drug ReS39 led to normalisation of elevated glucose levels in blood. In depth analysis revealed that both insulin resistance and β-cell function were markedly improved and the effect lasted even weeks after the treatment was stopped. These strong and durable effects were clearly superior to metformin, the current first-line treatment of choice after diet and exercise.
This diabetes program has been made possible by two grants of IWT, the Flemish institute providing grants to companies and academia in Flanders. reMYND will present the pre-clinical data of this program on May 8th, 2014 at Knowledge For Growth in Ghent.
